Key Highlights
- SYRS shares now trade for a fraction of a cent, a shadow of the Nasdaq-listed biotech that once carried a nine-figure valuation.
- Syros's lead effort, tamibarotene in the SELECT-MDS-1 Phase 3 trial, failed to meet its primary endpoint of complete response rate, triggering a Loan default with Oxford Finance.
- The company voluntarily Delisted from Nasdaq around March 2025 and filed to deregister with the SEC, entering an orderly wind-down under lender oversight.
- In Chapter-11-style wind-downs, Equity holders typically rank behind secured creditors, so residual recovery for common shareholders is often limited or nil.
Once a well-funded cancer-drug developer, Syros Pharmaceuticals has faded from public markets after a pivotal trial setback. Syros Pharmaceuticals (OTC: SYRS) now changes hands for a fraction of a cent, a shadow of the Nasdaq-listed biotech that once carried a nine-figure valuation. The quiet around the name is not the calm before a rebound; it reflects a company that voluntarily left Nasdaq in 2025 and entered an orderly wind-down. For investors scanning micro-cap tickers, the Syros story is a cautionary one.
Company and Latest Development
Syros Pharmaceuticals was a Cambridge, Massachusetts clinical-stage biopharmaceutical company focused on treatments for blood disorders and cancer, including myelodysplastic syndromes (MDS). Its lead effort centered on tamibarotene in the SELECT-MDS-1 Phase 3 trial. The company later disclosed that SELECT-MDS-1 failed to meet its primary endpoint of complete response rate, a result that triggered a default under its loan agreement with Oxford Finance and left the Balance Sheet under severe strain.
What Is Driving Attention Around SYRS?
Rather than a fresh catalyst, attention around SYRS stems from its collapse and delisting. In early 2025, Syros announced a voluntary delisting from the Nasdaq Global Select Market and deregistration with the SEC. It had fallen out of compliance with multiple Nasdaq listing standards: its bid price had sat below $1.00 for more than 35 consecutive Business days, its listed-securities value had dropped under $50 million, and its publicly held shares were valued below $15 million. The board concluded that ending its exchange listing and reporting obligations would preserve cash for an orderly wind-down. There is no verified public catalyst behind day-to-day moves in the shares; trading is thin and residual.
Key Numbers and Company Position
Syros filed a Form 25 with the SEC on or about March 10, 2025, with delisting effective around March 20, 2025, followed by a Form 15 to deregister; full deregistration was set to follow roughly 90 days later. The company said it was operating under a budget-restricted wind-down approved by its lender, Oxford Finance. Market-data providers now show Syros trading over the counter at deeply distressed levels, with a Market Value measured in the tens of thousands of dollars rather than the hundreds of millions it once carried.
What Could Come Next?
For a company in an orderly wind-down, the path is defined by asset resolution rather than growth. Possible developments include the sale or licensing of remaining pipeline Assets or intellectual property, settlement of obligations to Oxford Finance and other creditors, and distribution of any residual value to Stakeholders under the lender-approved plan. Absent SEC reporting, investors have limited visibility into the timing or outcome of these steps.
Risks to Watch
The risks here are acute and largely realized. Shares are no longer exchange-listed, Liquidity is minimal, and price discovery on the over-the-counter market can be erratic. Deregistration means reduced transparency and no ongoing quarterly financials. In a wind-down, equity holders typically rank behind secured creditors, so residual recovery for common shareholders is often limited or nil. Any position carries substantial risk of total loss.
A Biotech Unwinding, Not a Comeback Story in Waiting
Syros Pharmaceuticals is not a comeback story in waiting but a biotech unwinding after its lead Phase 3 program missed. The most important facts to monitor are structural: the status of the wind-down, creditor settlements with Oxford Finance, and whether any pipeline assets find a buyer. Investors encountering the SYRS ticker should recognize that it reflects a delisted, deregistered company in liquidation-style circumstances, and treat any residual quote with corresponding caution.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...